Abstract: Hepatocellular carcinoma (HCC), ranking as the sixth most common malignant tumor and the third leading cause of cancer‑related deaths globally, is experiencing an unprece-dented increase in disease burden. Without effective interventions, the number of new HCC cases worldwide is projected to rise from 870 000 in 2022 to 1.52 million by 2050, with annual deaths increasing from 760 000 to 1.37 million. In response to this critical challenge, China has achieved significant breakthroughs in HCC prevention and treatment in recent years. A series of domestically developed systemic therapies for HCC have been approved for clinical use. The CARES‑009 study has demonstrated for the first time that a perioperative "sandwich" therapeutic approach significant reducing recurrence risk in resectable HCC. The TALENTop study provides high‑level evidence supporting surgical resection after conversion therapy. The landmark Lancet Commission on Liver Cancer Prevention and Treatment, which is led by Chinese researchers in collaboration with 51 global experts, has formally been released, proposing for the first time a global action framework targeting 2050. The authors systematically review key advances in HCC prevention and treatment in 2025, encompassing epidemiological trends, perioperative therapeutic breakthroughs and their immunological mechanisms, exploration of conversion therapy, innovations in systemic treatment, and global strategic planning. It comprehensively elucidates how the Chinese approach is shaping a new paradigm in HCC management, contributing Chinese wisdom and strength to reducing the global burden of liver cancer.